TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02555332

Intervention type: OTHER
Intervention: 75g oral glucose tolerance test (OGTT)
Description: All these women underwent the 75g oral glucose tolerance test (OGTT) at 24-28 weeks of gestation.
Study: NCT04460820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Liposome Injection
Description: 50mg/m2,IV on Day 1 of each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride Liposome Injection
Description: 50mg/m2,IV on Day 1 of each cycle
Study: NCT00755131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-based Cardiac Rehabilitation program
Description: Trained patients attend the exercise training protocol for 6 months on hospital ambulatory-based regimen 3 times/week. Training sessions are supervised under continuous electrocardiography monitoring by a cardiologist, a physiotherapist and a graduate nurse. Each session is preceded by a 5-min warming-up and followed by a 5-min cooling-down. Exercise is performed for 30 min on a bicycle ergometer with the target of 60-70% of the peak oxygen consumption achieved at the initial symptom-limited cardiopulmonary exercise test. Exercise protocol is performed with a gradual increase in exercise workload until the achievement of the predefined target.
Study: NCT03449160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UPRIGHT
Description: A small externally wearable device that is placed on the back, which gently vibrates when correct posture is not maintained. The device is removable, and used for only portions of the day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: routine physical therapy
Study: NCT04455269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AIRFLOW® with PLUS® powder and PIEZON® scaler
Description: Air-polishing will be use as main instrument for biofilm and stains removal, followed by ultrasonic scaling

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PIEZON® scaler and rubber cup with abrasive paste
Description: Application of ultrasonic scaler on the entire dentition, followed by residual biofilm and stains removal and polishing
Study: NCT02740166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
Study: NCT04476875

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Open Outpatient Clinic Programme
Study: NCT05019989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group on diet and physical activity
Description: The intervention wanted to increase physical activity, controlling weight, promoting healthy diet.~1. Physical activity: achieve and maintain regular participation in a moderate intensity physical activity program of 210 minutes/week (30 min on average per day) over at least 3 days /week; decrease sedentary behaviors by 30 minutes/day on at least 5 days/week~2. Weight control: reducing energy intake relative to expenditure is the primary dietary focus for promoting weight loss in overweight or obese participants, and maintaining a healthy energy balance is the primary focus for normal weight participants. Participants will be encouraged to include whole grains and high-fiber vegetables~3. Healthy diet: reducing calorie intake, through the preferred consumptions of unrefined cereals, pulses and vegetables, reducing high glycemic index food and high insulinemic foods, such as sugar and milk; reducing sources of saturated fat and animal protein (except fish)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group: only public recommendation an lifestyle
Description: 1. Invitation leaflet, explaining the rationale of the study and including basic life-style recommendations, based on the 1997 World Cancer Research Fund recommendations (to be updated in 2007) and the Italian National Institute of Nutrition food pyramid.~2. Dissemination of the information on the study by media~3. Yearly follow-up questionnaire on breast events and dietary and physical activity chang
Study: NCT00238459

Intervention type: DRUG
Intervention: Patients elected to take licensed drugs. The vaccine was not provided for evaluation
Description: Note:In August 2007 we were notified by the manufacturer that the experimental vaccine was no longer being made and would no longer be available for this study. Too few participants have received the vaccine or placebo to conclude anything about potential efficacy

Intervention type: DRUG
Intervention: multiple licensed drugs not randomized

Intervention type: DRUG
Intervention: multiple licensed antiretroviral drugs; not randomized

Intervention type: OTHER
Intervention: Intended vaccine not provided, Licensed drugs provided, but were not investigated
Study: NCT02451891

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-EBO Z

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-EBO Z

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-EBO Z

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-EBO Z

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-EBO Z

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd3-EBO Z

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd3-EBO Z

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd3-EBO Z
Study: NCT01297088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-9596
Description: One single dose administration of a diagnostic agent
Study: NCT03062241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: After left atrial appendage (LAA) thrombus exclusion, the transseptal puncture will be performed and intravenous heparin will be administered to achieve Activated Clotting Time (ACT) ≥300 seconds.The pulmonary vein (PV) isolation will be performed. Optimal cryoballoon positioning will be confirmed by PVs angiography. Pulmonary veins isolation will be confirmed by entrance/exit block using appropriate catheter. During cryoablation of the right PVs, high-output right phrenic nerve stimulation will be performed using a diagnostic catheter placed in the superior vena cava. Whenever decrease/loss of pacing capture will be observed, cryoablation will be immediately terminated.
Study: NCT02006069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPP
Description: All patients enrolled in the study will be implanted (according to current Guidelines) with an MPP compatible CRT device.~The MPP feature will be evaluated in two study phases. Patients randomized to MPP in Phase I will have MPP programmed per the physician's discretion (no mandated MPP programming) and patients randomized to MPP in Phase II will have MPP programmed per protocol requirements (mandated MPP programming).
Study: NCT02989805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Management
Description: Professionals and peers will each deliver the same intervention. The intervention combines a traditional medical model of care management with a recovery-based approach.
Study: NCT00257894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Dosing taken orally for a total of 12 days: 40mg/day vs. 0mg/day (placebo tabs). The 40mg condition will receive 15mg/day the first 3 days(Days 1,2,3), 30mg/day for 3 days(Days 4,5,6), and 40mg/day for 3 days(Days 7,8,9). Downward titration: 40mg/day condition will receive 40mg/day(Day 10), 20mg/day(Day 11), and 10mg/day(Day 12).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo capsules containing inert filler taken orally for a total of 12 days
Study: NCT02989805

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care Management
Description: Professionals and peers will each deliver the same intervention. The intervention combines a traditional medical model of care management with a recovery-based approach.
Study: NCT03837288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerclage
Description: Cervical cerclage under effect of spinal anaesthesia
Study: NCT02955459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5133

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00952523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin Facial Gel
Description: A marketed facial gel containing Tretinoin 0.04% is applied to one side of the face daily for three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene/Benzoyl Peroxide Facial Gel
Description: A marketed facial gel containing Adapalene .1% and Benzoyl peroxide 2.5% is applied to the other side of the face daily for three weeks
Study: NCT04758520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLOAT upper limb exoskeleton
Description: The FLOAT device is composed by a wearable exoskeleton assembled on a poly-articulated arm that, in turn, is mounted on a support base with unlockable wheels. The exoskeleton includes 5 motors arranged in a way that, when generating movement, ensures the optimal involvement of all the articulations of the shoulder complex, particularly the glenohumeral and the scapulothoracic joints. According to the chosen modality of use of the exoskeleton, the device allows patient's passive or active-assisted mobilization. The poly-articulated arm supporting the exoskeleton is capable to compensate exoskeleton weight in every configuration and, if configured appropriately, permits exoskeleton use both in seated and standing positions. The support base of the device has unlockable wheels that, if unlocked, permit the free movement of the patient in the workspace, enabling the performance of more complex functional activities while assisted by the exoskeleton.
Study: NCT01839136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrauterine transfer of gametes
Study: NCT00423215

Intervention type: DRUG
Intervention: Insulin glargine (LANTUS)
Description: The patients will receive Lantus administered by subcutaneous injection, once daily at any time but at the same time each day.~Treatment duration: 4 months.
Study: NCT00572494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAGIC EXPLORER (Biotronik AG)
Description: The lesion is pre-dilated with the PLEON EXPLORER balloon with a length of 10 mm or 15 mm or 20 mm under angiographic control. After dilation, the stenosed area is treated by one AMS implant. If the implanted stent is not fully apposed to the vessel wall or if initial angiography reveals a residual stenosis, the stent may be post-dilated with the delivery system balloon. If necessary, a high-pressure, non-compliant balloon catheter may be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PLEON EXPLORER (Biotronik AG)
Description: The lesion is dilated with the PLEON EXPLORER balloon with lengths of 10 mm or 15 mm or 20 mm, respectively. In case that the PTA procedure results in a residual stenosis of \>50%, the AMS implant should be used to improve the result. A flow-limiting dissection does not qualify for stenting. Best effort must be made to obtain a satisfactory result (e.g. multiple and prolonged inflations) before a patient in the PTA group can be treated with a stent.
Study: NCT02393456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Description: Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
Study: NCT01839136

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine transfer of embryos
Study: NCT02903394

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mLCI Device
Description: imaging of cervical epithelium using mLCI device
Study: NCT01497184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HSCT
Description: Hematopoietic stem-cell transplant using cells from a matched family donor (matched related allogeneic HSCT) using a non-T cell depleted graft under standard of care procedures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HSCT
Description: Hematopoietic stem-cell transplant using cells from a matched family donor (matched related allogeneic HSCT) using a non-T cell depleted graft under standard of care procedures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HSCT
Description: Hematopoietic stem-cell transplant using cells from a matched family donor (matched related allogeneic HSCT) using a non-T cell depleted graft under standard of care procedures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HSCT
Description: Hematopoietic stem-cell transplant using cells from a matched family donor (matched related allogeneic HSCT) using a non-T cell depleted graft under standard of care procedures

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DLI
Description: Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10\^6/m\^2 intravenously between 6 weeks and 12 weeks following allogeneic HSCT.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DLI
Description: Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10\^6/m\^2 intravenously between 6 weeks and 12 weeks following allogeneic HSCT.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DLI
Description: Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10\^6/m\^2 intravenously between 6 weeks and 12 weeks following allogeneic HSCT.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DLI
Description: Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10\^6/m\^2 intravenously between 6 weeks and 12 weeks following allogeneic HSCT.
Study: NCT00476957

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent
Description: Stent implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent
Description: Stent implantation
Study: NCT02260726

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic resonance imaging
Study: NCT03067376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-CORT125134
Study: NCT02184832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 2 doses of 500 mg metformin given approximately 12 hrs apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 2 doses of 500 mg metformin given approximately 12 hrs apart

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low tryptophan diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High tryptophan diet
Study: NCT01657708

Intervention type: OTHER
Group type: OTHER
Intervention: Shared Decision Making
Study: NCT01755650

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F FPM

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F FPM
Study: NCT00660985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene
Description: Gel, 0.3%, 2g, once daily for 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene
Description: Gel, 0.1%, 2g, once daily for 30 days
Study: NCT02163785

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominoperineal extra-elevators rectal resection for low lying rectal cancer
Description: Abdominoperineal extra-elevators rectal resection for low lying rectal cancer involving anal sphincter complex

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominoperineal extra-elevators rectal resection for low lying rectal cancer
Description: Abdominoperineal extra-elevators rectal resection for low lying rectal cancer involving anal sphincter complex
Study: NCT01804309

Intervention type: PROCEDURE
Intervention: Sentinel lymph node biopsy (SLNB)
Description: The intervention (SLNB) is no different in the care of patients' in the study then in those who were not included in the past or will not be included after the trial terminates. SLNB is performed according to strict professional guidelines adopted by the National Institute of Oncology, Budapest, Hungary.
Study: NCT00909597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: 30mg po once daily for 4 weeks, followed by 45mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10mg sc once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10mg sc once weekly for 4 weeks, followed by 20 mg sc once weekly
Study: NCT03469024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Rehabilitation Program
Description: It consists in a home rehabilitation program performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: e-Health program
Description: It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
Study: NCT02541786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexlansoprazole based triple therapy
Description: dexlansoprazole MR 60 mg once daily+clarithromycin 500 mg twice daily+ amoxicillin 1 g twice daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole-based triple therapy
Description: rabeprazole 20 mg twice daily + clarithromycin 500 mg twice daily + amoxicillin 1 g twice daily for 7 days
Study: NCT00548717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study: NCT00537407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 025
Description: Debio 025 supplied as a 100 mg/mL oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 025
Description: Debio 025 supplied as a 100 mg/mL oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 025
Description: Debio 025 supplied as a 100 mg/mL oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 025
Description: Debio 025 supplied as a 100 mg/mL oral solution
Study: NCT01620073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV counseling and testing
Description: Male partner HIV counseling and testing

Intervention type: OTHER
Group type: OTHER
Intervention: HIV counseling and testing
Description: Male partner HIV counseling and testing
Study: NCT04467879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zona Plus Device
Description: Zona Plus 3.0 Individualized Isometric Handgrip Therapy Device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Device
Description: Zona Plus control sham device, with a nominal weaker grip
Study: NCT02129985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide (10 ug/bid for 3 months)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850 mg/bid for 3 months
Study: NCT03897179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00032 and INVSENSOR00033
Description: Investigational pulse oximeter device
Study: NCT03134482

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVM
Description: No gonadotropin is used, but hCG priming is utilized 36 hour before oocyte maturation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimal stimulation IVF
Description: IVF with minimal use of gonadotropin, i.e. 150 or less IU of recombinant FSH, followed by hCG triggering in GnRH antagonist protocol.
Study: NCT01480076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fampridine
Description: Supplied as a 10 mg twice daily tablet and taken twice daily. Doses must be spaced at least 12 hours apart.
Study: NCT00704535

Intervention type: DRUG
Intervention: Ezetimibe
Description: 1 tablet of 10 mg once daily